Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

R-DHAOx May Be ‘Attractive’ Salvage Option For Rel/Ref DLBCL

Key clinical point: Oxaliplatin, cytarabine, dexamethasone, and rituximab (R-DHAOx) produced responses and allowed for “optimal” stem cell collection in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Major finding: After two courses of R-DHAOx, the overall response rate was 60%, 21 of 22 eligible patients went on to stem cell harvest and transplant, and the 3-year overall survival rate was 40.5%.

Study details: A retrospective analysis of R-DHAOx in 53 patients with relapsed/refractory DLBCL.

Disclosures: The authors declared no conflicts of interest.

Citation:

Manconi L et al. Leuk Lymphoma. 2019 Sep 4:1-7. doi: 10.1080/10428194.2019.1658102.